Claim: Statins cause serious liver and kidney damage

First requested: August 25, 2026 at 2:31 PM
19%

IsItCap Score

Truth Potential Meter

Not Credible

AI consensusMedium

Grader consensus is moderate.
Range 15%–25% (spread Δ10).
The graders lean in the same direction but differ on strength. Skim the summary and sources.
Read analysis summary

OpenAI Grade

0%
20%
40%
60%
80%
25%

Perplexity Grade

0%
20%
40%
60%
80%
18%

Google Gemini Grade

0%
20%
40%
60%
80%
15%
Shareable summary
Verdict: Questionable
  • Mild, transient liver enzyme rises are more common than true injury.
  • Serious liver and kidney harm is described as rare, not typical.
/r/fact-check-statins-liver-kidney-damage

Analysis Summary

The claim that statins cause serious liver and kidney damage is mostly false. Mainstream medical sources, such as the Mayo Clinic and NCBI, indicate that serious harm is rare and typically associated with specific conditions like rhabdomyolysis. However, some studies report hepatotoxicity signals, suggesting that while the risk is low, it is not nonexistent. Critics argue that these rare cases do not warrant the broad claim of serious damage from statins, which is supported by the majority of medical literature. Thus, the evidence leans towards the safety of statins in typical use cases, despite some conflicting reports. All three graders point in the same direction, with minor differences. OpenAI comes in highest (25%), while Gemini is lowest (15%). Gemini expresses higher confidence than OpenAI on this claim. While some studies indicate potential hepatotoxicity associated with statins, these findings are often based on rare cases or specific conditions. The majority of reputable sources emphasize that serious liver injury is uncommon and that mild enzyme elevations do not equate to significant damage. This discrepancy does not fundamentally alter the overall assessment that statins are generally safe for most patients, but it does highlight the need for monitoring in specific populations or under certain conditions.
Jump to source analysis

Source quality

Truth (from sources)2.00 / 10
Source reliability8.00 / 10
Source independence7.00 / 10

Claim checks

Fits established facts6.00 / 10
Logical consistency5.00 / 10
Expert consensus4.00 / 10
Related fact checks

Source Analysis

Common arguments
Supporting the claim
  • FAERS signals can show possible liver safety concerns for some statins.
  • Higher doses may raise the chance of liver enzyme abnormalities.
  • Rare clinically apparent liver injury has been reported for rosuvastatin.
Against the claim
  • Mild, transient liver enzyme rises are more common than true injury.
  • Serious liver and kidney harm is described as rare, not typical.
  • Kidney injury is mainly tied to rare rhabdomyolysis, not standard use.

Mainstream Sources

Publication

Mayo Clinic

Title

Statin side effects: Weigh the benefits and risks

Summary

Mayo Clinic says serious liver and kidney harm is tied to rare rhabdomyolysis, not common statin use.

Source details

—

URL

Visit Source

Publication

NCBI Bookshelf

Title

Statins - LiverTox

Summary

LiverTox says statins usually cause only mild, transient liver enzyme elevations and rare clinically apparent liver injury.

Source details

—

URL

Visit Source

Publication

American Family Physician

Title

Considerations for Safe Use of Statins: Liver Enzyme Abnormalities and Muscle Toxicity

Summary

AAFP says true liver injury from statins is low and liver enzyme rises do not necessarily mean liver damage.

Source details

—

URL

Visit Source

Alternative Sources

Publication

PMC

Title

Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System

Summary

This pharmacovigilance study reports hepatotoxicity signals for several statins in adverse-event data.

Source details

—

URL

Visit Source

Publication

NCBI Bookshelf

Title

Atorvastatin - LiverTox

Summary

LiverTox notes a higher relative risk of moderate or serious liver dysfunction at higher doses and early in treatment, though the absolute risk is low.

Source details

—

URL

Visit Source

Publication

NCBI Bookshelf

Title

Rosuvastatin - LiverTox

Summary

LiverTox reports rare acute clinically apparent liver injury with rosuvastatin.

Source details

—

URL

Visit Source

Analysis Breakdown

True/False Spectrum (2.0)Source Credibility (8.0)Bias Assessment (7.0)Contextual Integrity (6.0)Content Coherence (5.0)Expert Consensus (4.0)53%

How to read the breakdown

Weakest areas
Truth2.0/10Consensus4.0/10
  • Truth: how well sources support the core claim.
  • Source reliability: whether the sources have a strong track record.
  • Independence: whether coverage looks one-sided or recycled.
  • Context: missing details (timeframe, definitions, scope) that change meaning.
  • Tip: if graders disagree, rely more on the summary + sources than the single number.

Detailed AnalysisPremium Feature

Get an in-depth analysis of content accuracy, source credibility, potential biases, contextual factors, claim origins, and hidden perspectives.

Create a free account to unlock premium features.

Methodology